Other languages Eyenovia, Inc.

Equities

EYEN

US30234E1047

Real-time Estimate Cboe BZX Other stock markets 10:51:31 2024-04-29 EDT			5-day change	1st Jan Change
0.698 ^USD	+11.11%		+33.24%	-66.91%

04-25	Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension	CI
04-08	Eyenovia to Weigh Potential Sale, Other Strategic Alternatives	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension	04-25
Eyenovia to Weigh Potential Sale, Other Strategic Alternatives	04-08
Eyenovia Explores Wide Range of Strategic Alternatives	04-08
Eyenovia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals	03-13
Eyenovia Reports FDA Approval for Formosa's Post-Op Eye Inflammation, Pain Treatment	03-05
US FDA approves Eyenovia's eye drug, Formosa Pharma says	03-04
Eyenovia, Inc Announces FDA Approval of Redwood City as Commercial Manufacturing Facility	02-13
Eyenovia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13
Eyenovia, Inc. Appoints Michael Geltzeiler to Serve on the Board and as the Chair of the Audit Committee of the Board	11-09
Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production	11-02
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	23-08-25
Eyenovia Prices $12 Million Registered Direct Offering	23-08-25
Insider Buy: Eyenovia	23-08-17
Eyenovia Acquires US Rights to Eye Surgery Drug From Formosa	23-08-16
Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of App13007 for the Treatment of Inflammation and Pain Following Ocular Surgery	23-08-16
Eyenovia, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Eyenovia, Inc. Announces First Commercial Sale of Mydcombi	23-08-03
Eyenovia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Eyenovia Gets FDA Approval for Mydcombi Ophthalmic Spray; Shares Fall	23-05-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Eyenovia, Inc.

Equities

EYEN

US30234E1047

Other languages

Filters